BIOMAT Database Logo BIOMAT Database Logo

Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate. 1998

W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Discovery Chemistry, Pharmacia & Upjohn, Inc., Kalamazoo, Michigan 49001-0199, USA.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D020008 Delavirdine A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Delavirdine Mesylate,Rescriptor,U-90152,U-90152S,Mesylate, Delavirdine,U 90152,U 90152S,U90152,U90152S

Related Publications

W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
January 1996, Advances in experimental medicine and biology,
W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.
December 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Once-daily nonnucleoside reverse-transcriptase inhibitor approved.
December 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
July 2009, AIDS (London, England),
W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Development of nonnucleoside HIV reverse transcriptase inhibitors.
January 1996, Methods in enzymology,
W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
May 2019, AIDS (London, England),
W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
May 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
April 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Nonnucleoside reverse transcriptase inhibitor marketed for AIDS therapy.
September 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
W J Adams, and P A Aristoff, and R K Jensen, and W Morozowich, and D L Romero, and W C Schinzer, and W G Tarpley, and R C Thomas
Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice.
July 1997, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!